Avalo Therapeutics (AVTX) Deferred Taxes (2017 - 2026)
Avalo Therapeutics posted quarterly Deferred Taxes of $12000.0 for Q1 2026, up 50.0% year-on-year from $8000.0 in Q1 2025, and down 90.84% on a QoQ basis from $131000.0 in Q4 2025.
Avalo Therapeutics (AVTX) has 10 years of Deferred Taxes data on file, last reported at $12000.0 in Q1 2026.
- For the quarter ending Q1 2026, Deferred Taxes rose 50.0% year-over-year to $12000.0; the trailing twelve-month figure through Mar 2026 stood at $169000.0 (up 46.96% YoY), and the FY2025 full-year result was $165000.0, up 44.74% from the prior year.
- Deferred Taxes for Q1 2026 stood at $12000.0, down from $131000.0 in the prior quarter.
- Across five years, Deferred Taxes topped out at $131000.0 in Q4 2025 and bottomed at -$14000.0 in Q3 2024.
- The 5-year median for Deferred Taxes is $8000.0 (2022), against an average of $19588.2.
- Peak annual rise in Deferred Taxes reached 1366.67% in 2024, while the deepest fall reached 275.0% in 2024.
- A 5-year view of Deferred Taxes shows it stood at $8000.0 in 2022, then slumped by 212.5% to -$9000.0 in 2023, then jumped by 1366.67% to $114000.0 in 2024, then gained by 14.91% to $131000.0 in 2025, then slumped by 90.84% to $12000.0 in 2026.
- The last three Deferred Taxes figures came in at $12000.0 (Q1 2026), $131000.0 (Q4 2025), and $10000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -859,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -65.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 96.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 9.31 Mn |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - | 12,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12,000.00 |
| Dec 31, 2025 | 131,000.00 |
| Sep 30, 2025 | 10,000.00 |
| Jun 30, 2025 | 16,000.00 |
| Mar 31, 2025 | 8,000.00 |
| Dec 31, 2024 | 114,000.00 |
| Sep 30, 2024 | -14,000.00 |
| Jun 30, 2024 | 7,000.00 |
| Mar 31, 2024 | 7,000.00 |
| Dec 31, 2023 | -9,000.00 |
| Sep 30, 2023 | 8,000.00 |
| Jun 30, 2023 | 7,000.00 |
| Mar 31, 2023 | 8,000.00 |
| Dec 31, 2022 | 8,000.00 |
| Sep 30, 2022 | 5,000.00 |
| Jun 30, 2022 | 6,000.00 |
| Mar 31, 2022 | 9,000.00 |
| Dec 31, 2021 | -62,000.00 |
| Sep 30, 2021 | 9,000.00 |
| Jun 30, 2021 | 10,000.00 |
| Mar 31, 2021 | 21,000.00 |
| Dec 31, 2020 | -226,000.00 |
| Sep 30, 2020 | 453,000.00 |
| Jun 30, 2020 | -445,000.00 |
| Mar 31, 2020 | 21,000.00 |
| Dec 31, 2019 | -45,566.00 |
| Sep 30, 2019 | 9,953.00 |
| Jun 30, 2019 | 12,929.00 |
| Mar 31, 2019 | 5,941.00 |
| Dec 31, 2018 | 31,249.00 |
| Sep 30, 2018 | -71,758.00 |
| Jun 30, 2018 | 7,851.00 |
| Mar 31, 2018 | 15,913.00 |
| Dec 31, 2017 | -832,629.00 |